Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Robert J. Mentz(Duke University), Justice Arhinful, Stephen J. Greene(Duke Medical Center), W. Herbert Haught, Freny Vaghaiwalla Mody, Ahmad Mizyed, Arthur L. Eberly, Jeffrey M. Testani(Yale University), Monique Robinson, James C. Fang, Mitchell A. Psotka(Alaska Heart and Vascular Institute), W.H. Wilson Tang(Cleveland Clinic), Jonathan D. Rich, Eric J. Velazquez(Yale University), Kelly Axsom, Bertram Pitt(Bayer (Germany)), Alain Heroux, Tracy A. DeWald, Fassil Ketema(National Heart Lung and Blood Institute), Gillian Grafton, Stephen S. Gottleib, Selim R. Krim, Patrice Desvigne‐Nickens(National Heart Lung and Blood Institute), John Rommel, Lokesh Tejwani, Kevin J. Anstrom(University of North Carolina at Chapel Hill), Michael D. McCulloch, Yair Lev, Adrian C. Bell, Hal A. Skopicki(Northwestern University), Shelby Morgan(Clinical Research Institute), B. Smith, Shelly Sapp(Clinical Research Institute), Eric L. Eisenstein(Clinical Research Institute), Anuradha Lala-Trindade, Justin Vader, Dong‐Yun Kim(National Heart Lung and Blood Institute), Dipanjan Banerjee, Preethi William, Kunal Bhatt(Emory University Hospital), Ernesto A. Ruiz Duque, Kirkwood F. Adams(University of North Carolina at Chapel Hill), Sandhya Murthy, Joshua Larned, Alexander A. Adler, Vandana Sachdev(National Heart Lung and Blood Institute), Amanda Harrington(Loyola University Chicago), Gerin R. Stevens
Cited by 180
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
|Nature Medicine|2013|4.4k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k